Ledraxen (Enoxaparin Sodium)

Ledraxen, a low molecular weight heparin, is indicated for several thrombo‑embolic conditions.

• Deep vein thrombosis (DVT): prevents clot formation and recurrence in at‑risk patients.
• Pulmonary embolism (PE): treats existing emboli and reduces the risk of new events.
• Anticoagulation during haemodialysis: maintains circuit patency by inhibiting clotting during the procedure.

• Enoxaparin Sodium potentiates antithrombin III, enhancing its inhibition of factor Xa and, to a lesser extent, factor IIa (thrombin). This selective blockade reduces thrombin generation and fibrin formation, thereby providing anticoagulant activity without markedly affecting platelet function.

Adverse reactions may occur with any anticoagulant therapy.

Common Side Effects

• Injection site reactions: erythema, pain, or bruising at the administration site.
• Mild bleeding: epistaxis, gum bleeding, or easy bruising.
• Gastrointestinal discomfort: nausea or dyspepsia.

Serious or Rare Side Effects

• Major hemorrhage: internal or intracranial bleeding requiring medical intervention.
• Heparin‑induced thrombocytopenia (HIT): immune‑mediated platelet decline with paradoxical clot risk.
• Severe allergic reactions: anaphylaxis, skin necrosis, or systemic hypersensitivity.

Before initiating Ledraxen, clinicians should evaluate bleeding risk and renal function.

• Renal impairment: adjust dose or monitor anti‑Xa levels in patients with reduced clearance.
• Active bleeding: avoid use unless the benefit outweighs the risk.
• Concomitant anticoagulants: assess necessity and monitor for additive bleeding.
• Surgical procedures: discontinue prior to invasive interventions as recommended.
• Pregnancy: consider only when maternal benefit justifies potential fetal risk.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ledraxen may interact with several drug classes, influencing bleeding risk.

Major Interactions (Avoid)

• Other anticoagulants (e.g., unfractionated heparin, warfarin, direct oral anticoagulants): markedly increased hemorrhage risk.
• Systemic thrombolytic agents (e.g., alteplase): additive bleeding potential.
• Antiplatelet agents (e.g., clopidogrel) when combined with high‑risk bleeding scenarios.

Moderate Interactions (Monitor Closely)

• Nonsteroidal anti‑inflammatory drugs (NSAIDs): may exacerbate minor bleeding.
• Selective serotonin reuptake inhibitors (SSRIs): potential for increased mucosal bleeding.
• Renal impairment: reduced clearance may necessitate dose adjustment and closer monitoring.